Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Capital Expenditures (2016 - 2025)

Voyager Therapeutics' Capital Expenditures history spans 11 years, with the latest figure at -$1.5 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 1095.48% year-over-year to -$1.5 million; the TTM value through Dec 2025 reached $427000.0, down 87.87%, while the annual FY2025 figure was $427000.0, 87.87% down from the prior year.
  • Capital Expenditures for Q4 2025 was -$1.5 million at Voyager Therapeutics, down from $207000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $2.4 million in Q3 2023 and bottomed at -$1.5 million in Q4 2022.
  • The 5-year median for Capital Expenditures is $316500.0 (2021), against an average of $441350.0.
  • The largest annual shift saw Capital Expenditures soared 476.92% in 2021 before it tumbled 1095.48% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $1.6 million in 2021, then crashed by 197.29% to -$1.5 million in 2022, then surged by 148.9% to $755000.0 in 2023, then crashed by 79.47% to $155000.0 in 2024, then crashed by 1095.48% to -$1.5 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Capital Expenditures are -$1.5 million (Q4 2025), $207000.0 (Q3 2025), and $1.1 million (Q2 2025).